{
    "clinical_study": {
        "@rank": "95691", 
        "arm_group": [
            {
                "arm_group_label": "HZ/su-PreChemo", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive the first dose of HZ/su at least 10 days (up to 1 month) before start of chemotherapy cycle.  The second dose of HZ/su vaccine will be administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy."
            }, 
            {
                "arm_group_label": "HZ/su-OnChemo", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive the first dose of HZ/su vaccine at the first day (allowing a window of +/- 1 day) of the first (or second) chemotherapy cycle.  The second dose of HZ/su vaccine will be administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy."
            }, 
            {
                "arm_group_label": "Placeb-PreChemo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects will receive the first dose of placebo at least 10 days (up to 1 month) before start of chemotherapy cycle. The second dose of placebo will be administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy."
            }, 
            {
                "arm_group_label": "Placeb-OnChemo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects will receive the first dose of placebo at the first day (allowing a window of +/- 1 day) of the first (or second) chemotherapy cycle.  The second dose of placebo will be administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals'\n      HZ/su vaccine in adults with solid tumours undergoing chemotherapy."
        }, 
        "brief_title": "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Herpes Zoster", 
        "condition_browse": {
            "mesh_term": "Herpes Zoster"
        }, 
        "detailed_description": {
            "textblock": "The study will be randomised into two groups based on the vaccination schedule in relation\n      to the start of chemotherapy:\n\n        -  The OnChemo group receives their first HZ/su vaccination at start of chemotherapy.\n\n        -  The PreChemo group receives their first HZ/su vaccination at least 10 days before start\n           of chemotherapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who, in the opinion of the investigator, can and will comply with the\n             requirements of the protocol.\n\n          -  Written informed consent obtained from the subject.\n\n          -  A male or female aged 18 years or older (and has reached the age of legal consent) at\n             the time of study entry (i.e., when informed consent is signed).\n\n          -  Subject who has been diagnosed with one or more solid tumours (defined as a solid\n             malignancy, i.e., not a blood element malignancy).\n\n          -  Subject who is receiving or will receive a cytotoxic or immunosuppressive\n             chemotherapy (such that the study vaccine can be administered at the latest at the\n             start of the second cycle of chemotherapy).\n\n          -  Life expectancy of greater than one year.\n\n          -  Female subjects of non-childbearing potential may be enrolled in the study:\n\n               -  Non-childbearing potential is defined as pre-menarche, current tubal ligation,\n                  hysterectomy, ovariectomy or post-menopause;\n\n          -  Female subjects of childbearing potential may be enrolled in the study, if the\n             subject:\n\n               -  has practiced adequate contraception for 30 days prior to vaccination, and\n\n               -  has a negative pregnancy test on the day of vaccination, and\n\n               -  has agreed to continue adequate contraception during the entire treatment period\n                  and for 2 months after completion of the vaccination series.\n\n        Exclusion Criteria:\n\n          -  Subjects receiving only newer, more targeted therapies if not taken together with a\n             classical chemotherapy.\n\n          -  Chronic administration and/or planned administration of systemic glucocorticoids\n             within one month prior to the first vaccine dose and up to Visit 3 (Month 2).\n             Inhaled, intra-articularly injected, and topical steroids are allowed.\n\n          -  Previous vaccination against HZ or varicella within 12 months preceding the first\n             dose of study vaccine/ placebo.\n\n          -  Planned administration during the study of a HZ vaccine (including an investigational\n             or non-registered vaccine) other than the study vaccine.\n\n          -  Previous chemotherapy course less than one month before first study vaccination.\n\n          -  Occurrence of a varicella or HZ episode by clinical history within the 12 months\n             preceding the first dose of study vaccine/ placebo.\n\n          -  History of allergic disease or reactions likely to be exacerbated by any component of\n             the vaccine or study material and equipment.\n\n          -  Administration or planned administration of a live vaccine in the period starting 30\n             days before the first dose of study vaccine and ending 30 days after the last dose of\n             study vaccine, or, administration or planned administration of a non-replicating\n             vaccine within 8 days prior to or within 14 days after either dose of study vaccine.\n\n          -  HIV infection by clinical history.\n\n          -  Acute disease and/or fever at the time of vaccination. Acute disease is defined as\n             the presence of a moderate or severe illness with or without fever, but excludes the\n             underlying malignancy, as well as the expected symptoms/signs associated with that\n             disease or its treatment:\n\n               -  Fever is defined as temperature \u2265 37.5\u00b0C /99.5\u00b0F on oral, axillary or tympanic\n                  setting, or \u2265 38.0\u00b0C /100.4\u00b0F on rectal setting. The preferred route for\n                  recording temperature in this study will be oral.\n\n               -  Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory\n                  infection) without fever, may receive the first dose of study vaccine/ placebo\n                  at the discretion of the investigator.\n\n          -  Any condition which, in the judgment of the investigator would make intramuscular\n             injection unsafe.\n\n          -  Pregnant or lactating female.\n\n          -  Female planning to become pregnant or planning to discontinue contraceptive\n             precautions (if of childbearing potential) before Month 3 (i.e., 2 months after the\n             last dose of study vaccine/ placebo)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "210", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01798056", 
            "org_study_id": "116427", 
            "secondary_id": "2012-002966-11"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "HZ/su-OnChemo", 
                    "HZ/su-PreChemo"
                ], 
                "description": "2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.", 
                "intervention_name": "GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Placeb-PreChemo", 
                    "Placeb-OnChemo"
                ], 
                "description": "2 doses administered by IM injection into the deltoid muscle of the non-dominant arm.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "\u226518 years of age", 
            "Chemotherapy", 
            "Solid tumours", 
            "Immunogenicity", 
            "Herpes Zoster", 
            "Safety", 
            "Shingles"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kelowna", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V1Y 5L3"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Halifax", 
                        "country": "Canada", 
                        "state": "Nova Scotia", 
                        "zip": "B3K 6R8"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M4C 3E7"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H4J 1C5"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 8", 
                        "country": "Czech Republic", 
                        "zip": "180 00"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Besan\u00e7on cedex", 
                        "country": "France", 
                        "zip": "25030"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ferolles-Attilly", 
                        "country": "France", 
                        "zip": "77150"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon Cedex 08", 
                        "country": "France", 
                        "zip": "69373"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34070"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nimes", 
                        "country": "France", 
                        "zip": "30907"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "110-744"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "138-736"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "136-705"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Badajoz", 
                        "country": "Spain", 
                        "zip": "6080"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28050"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28007"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28040"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28034"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Majadahonda (Madrid)", 
                        "country": "Spain", 
                        "zip": "28222"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00f3stoles", 
                        "country": "Spain", 
                        "zip": "28935"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pozuelo de Alarc\u00f3n/Madrid", 
                        "country": "Spain", 
                        "zip": "28223"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Sebastian de los Reyes", 
                        "country": "Spain", 
                        "zip": "28702"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cheltenham", 
                        "country": "United Kingdom", 
                        "state": "Gloucestershire", 
                        "zip": "GL53 7AN"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Woolwich", 
                        "country": "United Kingdom", 
                        "state": "London", 
                        "zip": "SE18 4QH"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Swindon", 
                        "country": "United Kingdom", 
                        "state": "Wiltshire", 
                        "zip": "SN3 6BB"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Exeter", 
                        "country": "United Kingdom", 
                        "zip": "EX2 5DW"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sheffield", 
                        "country": "United Kingdom", 
                        "zip": "S10 2SJ"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "York", 
                        "country": "United Kingdom", 
                        "zip": "YO31 8HE"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Canada", 
                "Czech Republic", 
                "France", 
                "Korea, Republic of", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "An Observer-blind Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults \u226518 Years of Age With Solid Tumours Receiving Chemotherapy", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Products and Food Branch of Health Canada", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Korea: Korea Food and Drug Administration (KFDA)", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Czech Republic: Statni ustav pro kontrolu leciv"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Anti-gE humoral immunogenicity with respect to components of the study/investigational vaccine in terms of antibody (Ab) concentrations.", 
                "safety_issue": "No", 
                "time_frame": "At Month 2."
            }, 
            {
                "measure": "Occurrence of solicited local and general symptoms.", 
                "safety_issue": "No", 
                "time_frame": "Within 7 days (Days 0-6) after each vaccination."
            }, 
            {
                "measure": "Occurrence of Unsolicited adverse events (AEs).", 
                "safety_issue": "No", 
                "time_frame": "During 30 days (Days 0-29) after each vaccination."
            }, 
            {
                "measure": "Occurrence of Serious Adverse Events (SAEs).", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 days post last vaccination."
            }, 
            {
                "measure": "Occurrence of AEs of specific interest.", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 days post last vaccination."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01798056"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "For immunogenicity with respect to components of the study/investigational vaccine in terms of antibody concentrations.", 
                "safety_issue": "No", 
                "time_frame": "At Month 0, Month 1, Month 6 (Visit 4, at the start of the last cycle of chemotherapy between months 4 and 13) and Month 13."
            }, 
            {
                "measure": "Occurrence of SAEs.", 
                "safety_issue": "No", 
                "time_frame": "During the period starting after 30 days post last vaccination until study end (Month 13)."
            }, 
            {
                "measure": "Occurrence of AEs of specific interest.", 
                "safety_issue": "No", 
                "time_frame": "During the period starting after 30 days post last vaccination until study end (Month 13)."
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}